⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DTIL News
Precision BioSciences, Inc. Common Stock
Form 8-K
sec.gov
DTIL
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
businesswire.com
DTIL
Form 8-K
sec.gov
DTIL
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
businesswire.com
DTIL
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
businesswire.com
DTIL
Form 8-K
sec.gov
DTIL
TGTX
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
businesswire.com
TGTX
DTIL
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
businesswire.com
DTIL
iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings
businesswire.com
DTIL
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
businesswire.com
DTIL